Quanterix Co. (NASDAQ:QTRX) Shares Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. boosted its position in Quanterix Co. (NASDAQ:QTRX) by 258.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,784 shares of the company’s stock after purchasing an additional 31,577 shares during the period. Fox Run Management L.L.C.’s holdings in Quanterix were worth $465,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in QTRX. Portolan Capital Management LLC raised its stake in shares of Quanterix by 31.4% during the 3rd quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company’s stock worth $32,668,000 after buying an additional 602,656 shares in the last quarter. William Blair Investment Management LLC purchased a new position in Quanterix in the fourth quarter worth $11,290,000. Geode Capital Management LLC lifted its holdings in Quanterix by 2.2% in the third quarter. Geode Capital Management LLC now owns 858,667 shares of the company’s stock valued at $11,131,000 after acquiring an additional 18,231 shares during the period. State Street Corp boosted its position in shares of Quanterix by 2.2% during the 3rd quarter. State Street Corp now owns 836,443 shares of the company’s stock worth $10,840,000 after purchasing an additional 18,050 shares in the last quarter. Finally, Pier Capital LLC grew its stake in shares of Quanterix by 23.5% during the 3rd quarter. Pier Capital LLC now owns 511,798 shares of the company’s stock worth $6,633,000 after purchasing an additional 97,256 shares during the period. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Stock Down 2.4 %

NASDAQ:QTRX opened at $7.02 on Wednesday. Quanterix Co. has a 52-week low of $6.30 and a 52-week high of $23.94. The stock has a fifty day simple moving average of $8.12 and a 200-day simple moving average of $10.75. The company has a market capitalization of $272.21 million, a PE ratio of -6.62 and a beta of 1.33.

Quanterix (NASDAQ:QTRX) last announced its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The business had revenue of $35.16 million for the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. As a group, equities analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Canaccord Genuity Group decreased their price objective on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Scotiabank reduced their price target on shares of Quanterix from $28.00 to $18.00 and set a “sector outperform” rating for the company in a research report on Tuesday.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.